Clinical Trial

Alternative Physical Activity Strategies for Breast Cancer Survivors

Study acronym: PACE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 2, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary aim of this study is to compare the acute glycemic effects of two novel, alternative physical activity (PA) strategies (dispersed post-meal PA, PA snacks) to a no PA condition and to exercise sessions representing the PA guidelines (standard 30-minute walking bout performed under fasting and under postprandial conditions and a standard 30-minute resistance training session) among sedentary breast cancer survivors who are currently receiving hormone therapies and age- and BMI-matched postmenopausal women without a history of cancer. The secondary aim is to determine whether the alternative PA strategies are acceptable and feasible in the free-living setting. An exploratory aim is to determine whether the outcomes differ between women with and without a history of breast cancer and use of aromatase inhibitors. The investigators hypothesize that: 1. Dispersed PA and PA snacks will result in greater reductions in 24-hour glucose and postprandial glucose compared to the no-PA baseline and similar reductions to a standard 30-minute bouts of walking; 2. The alternative PA strategies will be more feasible and have greater acceptability by cancer survivors compared to the standard 30-minute bout of walking or resistance training; and 3. The different PA strategies will have similar effects on glycemic outcomes for both breast cancer survivors and cancer-free controls. The resistance exercise session is an exploratory trial as the effects of it on acute glycemic control are understudied.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-07.
Status change: Not Yet Recruiting → Recruiting 2025-11-24
Trial Details
NCT Number NCT06633380
Lead Sponsor University of Toronto
Conditions Breast Cancer, Insulin Resistance, Cardiometabolic Risk Factors
Enrollment 24 participants
Start Date 2024-10-22
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-02